Quark Pharmaceuticals, Inc., the world leader in novel therapeutic RNAi discovery and development, has the largest clinical-stage siRNA pipeline in the industry. The Company’s fully integrated drug development platform spans therapeutic target identification to drug development. Quark’s approach to delivery allows targeting of tissues and organs including the eye, kidney, ear, lung, skin, spinal cord and brain. Quark has three siRNA product candidates in clinical development in five different disease indications of which two are in pivotal Phase III studies. Quark’s Joint Venture in China, Kunshan Ribo-Quark Pharmaceutical Inc, and its strategic partner in India, Biocon Limited, are part of Quark’s worldwide clinical studies network. Quark is headquartered in Fremont, California and operates research and development facilities in Boulder, Colorado and Ness-Ziona, Israel.
Fremont, US
Size (employees)
78 (est)-1%
Quark Pharmaceuticals was founded in 1994 and is headquartered in Fremont, US
Report incorrect company information

Key People/Management at Quark Pharmaceuticals

Daniel Zurr

Daniel Zurr

President and CEO
Rami Skaliter

Rami Skaliter

Shai Erlich

Shai Erlich

Chief Development Officer

Quark Pharmaceuticals Office Locations

Quark Pharmaceuticals has an office in Fremont
Fremont, US (HQ)
6501 Dumbarton Circle.
Show all (1)
Report incorrect company information

Quark Pharmaceuticals Financials and Metrics

Summary Metrics

Founding Date


Total Funding

$37 m

Latest funding size

$10 m

Time since last funding

8 years ago


Quark Pharmaceuticals's latest funding round in June 2010 was reported to be $10 m. In total, Quark Pharmaceuticals has raised $37 m
Show all financial metrics
Report incorrect company information

Quark Pharmaceuticals Online and Social Media Presence

Embed Graph
Report incorrect company information